PTK2 and esophageal squamous cell carcinoma: Interestingly, the FAK inhibitor VS-6063 (0.5–10 μM) inhibited AKT activation in ESCC cells incubated with pol-TAMs or CCL22 (50 ng/ml) more significantly than in control ESCC cells (Fig. 4D).